The Combined Blockade of β-Adrenoceptor and COX-2 During the Perioperative Period to Improve Long-term Cancer Outcomes.
*Neuroimmunology Research Unit, Sagol School of Neuroscience, and The School of Psychological Sciences, Tel-Aviv University, Tel-Aviv, Israel †Department of Cancer Anaesthesia, Pain and Perioperative Medicine, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.
Itay
I
Ricon
Jonathan G
JG
Hiller
Shamgar
S
Ben-Eliyahu
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D002395:Catecholamines / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D018450:Disease Progression; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D009369:Neoplasms / Q000378:metabolism / Q000601:surgery*; D019990:Perioperative Care; D059035:Perioperative Period; D011183:Postoperative Complications / Q000188:drug therapy / Q000209:etiology; D011448:Prostaglandin Antagonists / Q000009:adverse effects / Q000494:pharmacology*; D011453:Prostaglandins / Q000378:metabolism; D011941:Receptors, Adrenergic; D013312:Stress, Physiological / Q000187:drug effects; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000894:Anti-Inflammatory Agents, Non-Steroidal; D002395:Catecholamines; D052246:Cyclooxygenase 2 Inhibitors; D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D011941:Receptors, Adrenergic